Uncover key drivers, emerging technologies, and competitive movements shaping the diphtheria market from 2026–2035 with trusted insights from The Business Research Company
What upper market value could the Diphtheria Market reach by 2030 starting from 2026 levels?
The market size for diphtheria has experienced robust growth in recent years. It is forecast to expand from $9.39 billion in 2025 to $9.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.1%. This historical growth can be linked to past disease outbreaks, insufficient vaccination coverage, inadequate sanitation, a scarcity of early diagnostic tools, and disparities in healthcare access.
The diphtheria market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $13.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period stems from factors such as worldwide immunization drives, better access to diagnostics, increased public health funding, the digitalization of disease surveillance, and robust outbreak preparedness initiatives. Key trends anticipated over the forecast period encompass an ongoing need for vaccination and immunization efforts, a heightened emphasis on prompt diagnosis and monitoring, the expanding application of antibiotic and antitoxin treatments, the broadening of public health awareness campaigns, and the reinforcement of infectious disease tracking systems.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13016&type=smp
Which Drivers Are Influencing Long-Term Growth In The Diphtheria Market?
An increase in bacterial infections is anticipated to boost the expansion of the diphtheria market in the future. A bacterial infection refers to an illness or state caused by the multiplication of bacteria or the harmful substances they generate within the body. Diphtheria constitutes a severe infection resulting from specific bacterial strains that weaken the immune system and facilitate the increase of Corynebacterium diphtheria. As an illustration, data from March 2024, provided by the Centers for Disease Control and Prevention, a US-based government agency, indicated an escalation in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, marking an increment of 1,295 cases. Consequently, the growing occurrence of bacterial infections will stimulate the diphtheria market.
How Is The Diphtheria Market Divided Into Segments?
The diphtheria market covered in this report is segmented –
1) By Type: Diphtheria, Skin Diphtheria, Other Types
2) By Diagnosis: Physical Examination, Throat Culture, Other Diagnosis
3) By Treatment: Antibiotics, Antitoxin, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Diphtheria: Respiratory Diphtheria, Non-respiratory Diphtheria
2) By Skin Diphtheria: Cutaneous Diphtheria
3) By Other Types: Diphtheritic Myocarditis, Diphtheritic Neuritis
What Trends Are Reshaping The Dynamics Of The Diphtheria Market?
Key companies operating in the diphtheria market are focusing on integrating advanced formulation approaches, particularly thermostabilisation technology, to boost distribution efficiency, improve temperature resilience, and achieve independence from cold chains. Thermostabilisation techniques are sophisticated formulation methods engineered to protect vaccine antigens from degradation caused by heat or temperature variations, thereby enabling capabilities like room-temperature stability, reduced product wastage, and enhanced last-mile delivery. As an example, in April 2025, Stablepharma Ltd, a biotechnology firm based in the UK, commenced Phase 1 clinical trials for SPVX02. This innovative fridge-free tetanus–diphtheria vaccine is developed to retain its potency after exposure to temperature cycles ranging from -20°C to +40°C, providing up to 18 months of room-temperature shelf life through heat-resilient antigen preservation and offering significant potential for cold-chain-free deployment. SPVX02 is expected to enhance vaccine stability, improve supply-chain reliability, and broaden access in regions with limited infrastructure.
Which Leading Companies Dominate The Diphtheria Market Share?
Major companies operating in the diphtheria market are Sanofi Pasteur, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Biological E Limited, Bharat Biotech International Limited, Panacea Biotec Ltd, Mitsubishi Tanabe Pharma Corporation, KM Biologics (Meiji Holdings), AJ Vaccines, Bionet-Asia, Wuhan Institute of Biological Products, Walvax Biotechnology Co Ltd, Chengdu Institute of Biological Products Co Ltd, Minhai Biotechnology, Bio Farma Persero, Indian Immunologicals Ltd, LG Chem Ltd, Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, MassBiologics, Shanghai Institute of Biological Products Co Ltd, Changchun Institute of Biological Products Co Ltd, Hualan Biological Engineering Inc, Valneva SE, Pasteur Institute of India, Beijing Tiantan Biological Products Co Ltd, Chongqing Zhifei Biological Products Co Ltd, Shenzhen Kangtai Biological Products Co Ltd.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/diphtheria-global-market-report
How Does The Diphtheria Market Perform Across Major Global Regions?
Asia-Pacific was the largest region in the diphtheria market in 2025. The regions covered in the diphtheria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Diphtheria Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13016&type=smp
Browse Through More Reports Similar to the Global Diphtheria Market 2026, By The Business Research Company
Naphthalene Sulfonate Market Report 2026
https://www.thebusinessresearchcompany.com/report/naphthalene-sulfonate-global-market-report
Porcine Epidemic Diarrhea Vaccines Market Report 2026
Lenalidomide Market Report 2026
https://www.thebusinessresearchcompany.com/report/lenalidomide-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model